Orthopaedic Surgery, 2021 Objective To compare the preventive effects of teriparatide and alendronate on the progression of vertebral body collapse in postmenopausal single‐level Kümmell's disease (KD).
Peng‐guo Gou +8 more
doaj +1 more source
Comparison of osteoporosis pharmacotherapy fracture rates: Analysis of a marketScan® claims database cohort [PDF]
, 2018 Background: Several different classes of medications have been shown to be efficacious at preventing fractures in patients with osteoporosis. No study has compared real world efficacy at preventing fractures between all currently approved medications ...
Fox, Edward J. +5 more
core +2 more sources
Остеопороз и остеопатии, 2013 This review of the literature has been dedicated to experimental and clinical studies of mechanism of action and efficacy of 1—34 amino acid fragment of parathyroid hormone — teriparatide as well as others contries experience of its prescribtion ...
Zh E BELAYa, L Ya ROZhINSKAYa
doaj +1 more source
Enhancement of ghrelin-signaling system by Rikkunshi-To attenuates teriparatide-induced pica in rats
Journal of Pharmacological Sciences, 2018 Teriparatide is clinically used for the treatment of osteoporosis; however, nausea is often observed in patients. Its insufficient control affects the ability to continue teriparatide therapy.
Kouichi Yamamoto +3 more
doaj +1 more source
Bisphosphonate's and Intermittent Parathyroid Hormone's Effect on Human Spinal Fusion: A Systematic Review of the Literature. [PDF]
, 2017 There has been a conscious effort to address osteoporosis in the aging population. As bisphosphonate and intermittent parathyroid hormone (PTH) therapy become more widely prescribed to treat osteoporosis, it is important to understand their effects on ...
Acosta, Frank L +9 more
core +2 more sources
Positioning novel biologicals in CKD-mineral and bone disorders [PDF]
, 2017 Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD),
Covic, Adrian +5 more
core +1 more source
Suitability of teriparatide and level of acceptance of pharmacotherapeutic recommendations in a healthcare management areaSuitability of teriparatide and level of acceptance of pharmacotherapeutic recommendations in a healthcare management area DOI: 10.7399/fh.2016.40.4.9953 [PDF]
Farmacia Hospitalaria, 2016 Objective: To analyse the suitability of teriparatide prescriptions for osteoporosis treatment in a health management area, as well as the level of acceptance of pharmacotherapeutic recommendations made to physicians. Design: A prospective interventional
Maria Rosa Cantudo-Cuenca +5 more
doaj +1 more source
Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study [PDF]
, 2018 Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532).
Binkley +17 more
core +2 more sources
Teriparatide in the management of osteoporosis
Clinical Interventions in Aging, 2008 Fracture of the hip is frequently a catastrophic event in the elderly, often resulting in death within a year and of the survivors, few regain pre-fracture quality of life. Although less appreciated, fractures of the spine result in significant morbidity and are also associated with increased mortality compared with individuals without a fracture.
Donald L. Bodenner +2 more
openaire +4 more sources
JBMR Plus, 2019 Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture.
Takahiro Mori +2 more
doaj +1 more source